Kangstem Biotech Co. Ltd (217730) — Cash Flow-to-Debt Ratio
Kangstem Biotech Co. Ltd (217730) has a Cash Flow-to-Debt Ratio of -0.28x as of March 2026, meaning its operating cash flow of ₩-3.47 Billion could theoretically repay 0% of its total liabilities (₩12.20 Billion) in one year. Explore 217730 long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Kangstem Biotech Co. Ltd Cash Flow-to-Debt Ratio (2015–2025)
Historical debt coverage capacity for Kangstem Biotech Co. Ltd across 11 annual periods. Also explore Kangstem Biotech Co. Ltd assets under control for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Kangstem Biotech Co. Ltd (2015–2025)
Year-by-year debt coverage analysis for Kangstem Biotech Co. Ltd. For market capitalisation and broader financial context, see Kangstem Biotech Co. Ltd market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.94x | ₩-11.68 Billion | ₩12.43 Billion | ▲ +36.7% |
| 2024 | -1.48x | ₩-18.99 Billion | ₩12.80 Billion | ▼ -230.2% |
| 2023 | -0.45x | ₩-16.50 Billion | ₩36.74 Billion | ▲ +20.6% |
| 2022 | -0.57x | ₩-18.86 Billion | ₩33.33 Billion | ▼ -16.8% |
| 2021 | -0.48x | ₩-16.99 Billion | ₩35.07 Billion | ▼ -6.9% |
| 2020 | -0.45x | ₩-13.99 Billion | ₩30.89 Billion | ▼ -46.0% |
| 2019 | -0.31x | ₩-13.32 Billion | ₩42.92 Billion | ▲ +31.0% |
| 2018 | -0.45x | ₩-11.48 Billion | ₩25.50 Billion | ▲ +5.2% |
| 2017 | -0.47x | ₩-10.65 Billion | ₩22.44 Billion | ▼ -48.9% |
| 2016 | -0.32x | ₩-7.80 Billion | ₩24.46 Billion | ▲ +68.6% |
| 2015 | -1.01x | ₩-3.80 Billion | ₩3.75 Billion | — |